These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38712995)

  • 1. Chronic antibiotic suppressive therapy with dalbavancin: a case series.
    Pallotto C; Tommasi A; Albagini M; Genga G; Svizzeretto E; Gidari A; Tordi S; Francisci D
    J Chemother; 2024 May; ():1-5. PubMed ID: 38712995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.
    Bao H; Igwilo-Alaneme R; Sonia F; Cowman K; Kahn M; Nori P
    Ther Adv Infect Dis; 2024; 11():20499361241245523. PubMed ID: 38645297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
    McSorley JC; Reyes D; Tonna I; Bateman V
    Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current and future off-label uses of dalbavancin: a narrative review.
    De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety.
    Ruiz-Sancho A; Núñez-Núñez M; Castelo-Corral L; Martínez-Marcos FJ; Lois-Martínez N; Abdul-Aziz MH; Vinuesa-García D
    Front Pharmacol; 2023; 14():1185602. PubMed ID: 37448966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
    Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
    Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections.
    Rowe S; Green S; Albrecht B; Pouch SM
    Open Forum Infect Dis; 2023 Nov; 10(11):ofad537. PubMed ID: 38023541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
    Arrieta-Loitegui M; Caro-Teller JM; Ortiz-Pérez S; López-Medrano F; San Juan-Garrido R; Ferrari-Piquero JM
    Eur J Hosp Pharm; 2022 Jan; 29(1):55-58. PubMed ID: 33020060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
    Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
    Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
    Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection.
    Lange A; Thunberg U; Söderquist B
    BMC Infect Dis; 2023 Oct; 23(1):706. PubMed ID: 37858087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
    Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
    Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
    Gonzalez PL; Rappo U; Mas Casullo V; Akinapelli K; McGregor JS; Nelson J; Nowak M; Puttagunta S; Dunne MW
    Infect Dis Ther; 2021 Mar; 10(1):471-481. PubMed ID: 33515414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant
    Mazzitelli M; Gatti M; Scaglione V; Mengato D; Trevenzoli M; Sattin A; Pea F; Cattelan AM
    Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study.
    Courjon J; Senneville E; Illes HG; Pavese P; Boutoille D; Daoud FC; Dunkel N; Tattevin P
    Int J Antimicrob Agents; 2023 Oct; 62(4):106945. PubMed ID: 37543122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
    Simonetti O; Rizzetto G; Molinelli E; Cirioni O; Offidani A
    Ther Clin Risk Manag; 2021; 17():223-232. PubMed ID: 33790563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections.
    Wang Y; Wang J; Wang R; Li Y; Cai Y
    J Glob Antimicrob Resist; 2021 Mar; 24():72-80. PubMed ID: 33279683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.